Promising Drug Candidates And New Approaches To Unmet Medical Needs Give These 2 Biotech Stocks Over 50% Upside Potential

“Investors in biotech stocks need to find targets with positive catalysts on the near- to mid-term horizon, including promising drug candidates and/or novel approaches to unmet medical needs,” notes the author of today’s article, who proceeds to highlight two clinical-stage biotech stocks that appear to fit this profile – and where analysts see over 50% upside potential. For these two biotechs – including a company offering investors a chance to get in on the ground floor of a novel approach to treating hearing loss – CLICK HERE.